Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 20, 2018
Reporting Period: Fourth Quarter and Full Year ended December 31, 2017
This filing serves as a notification that the company issued a press release on February 20, 2018, announcing its financial results for the specified periods. The detailed results are contained in Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced press release (Exhibit 99.1) and are not present in the source text provided.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. It only confirms the announcement of results for the fourth quarter and full year 2017.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The company expressly disclaims any obligation to release publicly any updates or changes in expectations, events, conditions, or circumstances on which forward-looking statements are based.
- Legal Disclaimer: Information in this report is furnished pursuant to Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Exchange Act. It shall not be incorporated by reference into any Securities Act or Exchange Act filings.
- Website Availability: The text notes that the press release is available on the company website but reserves the right to discontinue availability at any time.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 20, 2018) for actual revenue, net income, and cash flow figures.
- Verify the specific details of the fourth quarter and full-year 2017 performance against prior year guidance.
- Confirm the company's current liquidity position and debt obligations as detailed in the full press release.
- Note the explicit disclaimer regarding future updates to forward-looking statements.